Job Description
The technical cooperation module project Strengthening Crisis and Pandemic Response in Africa (Support for Africa CDC) was commissioned by the Federal Ministry for Economic Cooperation and Development (BMZ) in December 2021. The overall objective of the project is to ‘strengthen the resilience of Africa CDC and related continental health institutions’, in line with the Agenda 2063 goal on achieving a safer, healthier, integrated and prosperous Africa, in which Member States can efficiently prevent disease transmission, implement surveillance and detection, and prepare to respond effectively to health threats and outbreaks. Context: Côte d'Ivoire Côte d'Ivoire is facing a growing proliferation of counterfeit medicines, threatening public health, the economy, and patient safety. According to studies conducted by the WHO in 2017, about 10 to 15% of medicines in circulation worldwide are falsified, in low- and middle-income countries this can be up to 40 to 50%, particularly in Africa. Côte d’Ivoire is not spared from this challenge which poses a threat to the overall health of its population. Numerous reforms have been initiated by the Government of Côte d'Ivoire since 2013, aimed at improving performance in the field of pharmaceutical regulation, through the establishment of the AIRP (Ivorian Authority of Pharmaceutical Regulation) via Law 2017-541 of August 3, 2017, concerning the regulation of the pharmaceutical sector, as well as the ratification of the MEDICRIME convention (July 20, 2023). Despite the efforts made by the Government, the illicit market for substandard medicines is intensifying in Côte d'Ivoire. It is currently difficult to assess the prevalence and distribution of substandard and falsified medical products (SFMP) in Côte d'Ivoire (and in many other countries). It is a complex challenge due to several interdependent factors, including: the persistence of informal markets, cross-border trade with illegal imports between neighboring countries (Ghana, Nigeria, Benin), and the existence of secret local manufacturing. According to Article 7 of Law No. 2017-541 of August 3, 2017, regarding the regulation of the pharmaceutical sector, the AIRP is responsible for overseeing the fight against counterfeit medicines and the illicit market for pharmaceutical products. Period of assignment: from 03.10.2025 until 01.04.2026. Key expert 1 Tasks of key expert 1 Overall responsibility for the advisory packages of the contractor (quality and deadlines) Coordinating and ensuring communication with GIZ, partners and others involved in the project Regular reporting in accordance with deadlines Qualifications of key expert 1 Education/training (2.2.1): university degree (Master) in Public Health, Epidemiology, or a related field Language (2.2.2): C1 -level language proficiencyin French General professional experience (2.2.3): 7 years of experience in pharmaceutical quality assurance, public health research, or regulatory systems. Specific professional experience (2.2.4): Demonstrated experience of conducting prevalence studies or medicine quality assessments. Familiarity with WHO guidelines on SF medicines and quality control procedures. Strong analytical and report-writing skills. Proficiency in qualitative/quantitative survey methods, Ability to work with public institutions and NGOs. Regional experience (2.2.6): 7 years of experience in projects in Africa (region), experience in West Africa (Ivory Coast is a plus).
How to Apply
Please request all tender documents by email from
AU\[email protected] mentioning "
83494514 Consultancy to Conduct a Prevalence Study" on the subject email. Tender documents include: · - GIZ invitation letter - Bidding conditions - General Terms and Conditions of Contract (AVB local) - Terms of Reference (ToR)\_ENG - Terms of Reference (ToR)\_FR - Technical assessment grid - Price Sheet - Eligibility Self Declaration - Extract from Act against Restraints on Competition (GWB)